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Early menopause or premature ovarian insufficiency (POI) is a common cause of infertility in women 
and affects about one per cent of young women. This disorder has significant psychological sequelae 
and major health implications. Its relevance has increased in recent years due to the fact that age of 
motherhood is being delayed in developed countries, with the risk of having either primary ovarian 
insufficiency or less possibilities of pregnancy. The main characteristics are absence of ovulation, 
amenorrhoea and high levels of serum gonadotropins (hypergonadotropic hypogonadism). Although the 
aetiology remains uncertain in most cases, several rare specific causes have been elucidated. Potential 
causes for POI are iatrogenic (ovarian surgery, radiotherapy or chemotherapy), environmental factors, 
viral infections, metabolic and autoimmune diseases, and genetic alterations. Because of the association 
with other autoimmune diseases, close follow up is recommended in patients with POI. The traditional 
indicators to evaluate ovarian ageing are age, serum hormonal levels, anti-Mullerian hormone, antral 
follicle count, and ultrasonography of ovaries. Hormone replacement therapy remains the mainstay of 
treatment, and the best chance of achieving a pregnancy is through oocyte donation. This article aims to 
present an overview of potential causes, clinical manifestations, and treatment options of POI.
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INTRODUCTION
 The women fertility reduces in parallel with 
the ageing1. Premature ovarian insufficiency (POI), 
commonly referred to as premature ovarian failure 
(POF) is a disorder characterized by dysfunction of the 
ovary before 40 years of age. The main characteristics 
include absence of ovulation, amenorrhoea and high 
levels of serum gonadothropins (hypergonadotropic 
hypogonadism, HH). POF is not uncommon; its 
incidence is estimated to be as high as 1 in 100 by the 
age of 40, and 1 in 1000 by the age of 30 years1,2. 
 As early as in 1930s, physicians noted abnormally 
elevated urinary gonadotropin levels in “premature 
menopause”. In 1950, Atria3 observed 20 patients with 
“precocious menopause” and defined the basic clinical 
features of POI, including amenorrhoea before the age 
of 40, clinical manifestations of hypoestrogenism, an 
association with viral sickness, and the efficacy of 
hormonal treatment. 
 Ovarian ageing resulting in ovarian failure and 
menopause is a continous process4. Menopause generally 
occurs around 51 yr of age, with an age range varying 
between 40 and 60 yr1,2,5.  The World Health Organization 
(WHO) defines menopause as the permanent cessation 
of menstruation due to the loss of ovarian follicular 
activity5. The final menstrual period is retrospectively 
assigned after 12 months of amenorrhoea. During the 
Stages of Reproductive Aging Workshop (STRAW) 
the criteria were formulated to distinguish the various 
stages of reproductive ageing, based on menstrual 
cycle pattern and follicle stimulating hormone (FSH) 
levels: (i) the (early, broad and late) reproductive stage, 
(ii) the (early and late) menopausal transition, and (iii) 
the (early and late) postmenopause. Cycles in the early 
menopausal transition are characterized by elevated but 
variable early follicular phase FSH levels and low anti-
Müllerian hormone (AMH) levels and antral follicle 
count (AFC)6. Menstrual cycles in the late menopausal 
transition are described by increased variability in 
cycle length, extreme variations in hormonal levels, 
and increased prevalence of anovulation6.
 POI is defined as the occurrence of amenorrhoea 
(for 4 months or more) before the age of 40 in women, 
accompanied with an increase of serum FSH to 
menopausal level (usually over 40 IU/l, obtained at 
least 1 month apart) and estradiol levels less than 50 
pg/ml (which signifies hypoestrogenism)7. Another 
indicator is the AMH, whose serum levels can help 
assess the state of follicular senescence, which is a 
possible predictor of risk for POI8. Howewer, there 
are presently no single screening test that can predict 
a woman’s reproductive lifespan. Serum hormonal 
levels, AMH, AFC and ultrasonography of ovaries, 
together with age are traditional signs to evaluate 
ovarian ageing9. The conception of ovarian reserve 
is the assessment of the reproductive ability as a 
function of the number and quality of residual oocytes. 
Decreased or diminished ovarian reserve (DOR) 
describes patients of reproductive age having regular 
menses whose response to ovarian stimulation or 
fertility is reduced compared with women of similar 
age. DOR is different from menopause or POI10.
 As yet, there are no well-established diagnostic 
criteria but differential diagnosis is needed to 
discount pregnancy, and other underlying conditions 
causing secundary amenorrhoea such as polycystic 
ovary syndrome (PCOS), hypothalamic disease, or 
uncontrolled diabetes mellitus11. Potential causes for 
POF are iatrogenic (ovarian surgery, radiotherapy or 
chemotherapy), environmental factors, viral infections, 
metabolic and autoimmune diseases, and genetic 
alterations, although its origin is idiopathic, and 
probably genetic in most cases12 (Table). This article 
provides an overview of potential aetiologies, clinical 
manifestations, and treatment modalities of POI.
ANATOMY AND PHYSIOLOGY
Determination of follicle number
 The stock of primordial follicles (oocytes 
surrounded by granulosa cells) in the ovaries, 
established before birth, has to supply the reproductive 
needs of a woman for the lifetime. The number of 
primordial follicles having potential to develop into 
a fertilizable oocyte is one component of the ovarian 
reserve13. At about 20 wk of foetal life, a maximum 
number of about 7 million germ cells is reached14,15. At 
birth and at menarche, about 1,000,000 and 3,00,000 
are left, respectively, of which only 400-500 follicles 
will develop fully and ovulate over the next 35-40 
years. At a mean age of 37-38 yr, only about 25,000 
resting follicles are present in the ovaries. Menstrual 
cycles become irregular at about age 45, which is on 
average six years at the (pre) menopause6.
 It is uncertain why so many germ cells are lost 
during the development of the primordial follicle 
pool. Once shaped, primordial follicles are recruited 
throughout life to enter folliculogenesis. The ovarian 
reserve can be influenced at multiple points during 
development and folliculogenesis: (i) primordial germ 
cell migration and proliferation; (ii) oocyte entry into 
meiosis I, synapsis, recombination and arrest in dictyate 














 HERNÁNDEZ-ANGELES & CASTELO-BRANCO: EARLY MENOPAUSE, DISADVANTAGE & RISK 421
422  INDIAN J MED RES, APRIL 2016
stage; (iii) transition from oocyte clusters to primordial 
follicles; (iv) primordial follicle activation; and (v) 
deficiencies in folliculogenesis or ovulation. The first 
three phases occur at the foetal and therefore, are not 
likely to be relevant in clinical treatment of infertility. 
The current and long-held dogma has been that the 
number of primordial follicles at birth represents the 
total ovarian reserve for the entire length of reproductive 
life; howewer, contradictory information suggest 
that oocyte “stem cells” continuosly contribute to the 
ovarian reserve13,16. The remarkably good result of in 
vitro fertilization (IVF) in (pre)menopausal women 
when employing oocytes of young donors further 
highlights that the oocyte rather than the endometrium 
determines the age-dependent fertility loss17.
 Only in the case of fecundation is the second 
division completed and therefore, all stages are under 
the influence of certain signals, and the entire process 
may last for many decades. It is suggested that oocyte 
derived factors, such as growth differentiation factor 9 
(GDF9) or bone morphogenetic protein 15 (BMP15) 
may be effective in regulating folliculogenesis18.
Endocrinological factors in ovarian ageing
 From the time of puberty onward, the GnRH 
(gonadotropin releasing hormone) pulse generator 
communicates with the pituitary gland through 
the pulsatile secretion of GnRH, which in turn 
communicates with the ovaries through the secretion 
of FSH and luteinizing hormone (LH). At each level of 
this communication system, multiple neuro endocrine 
molecules orchestrate precise positive and negative 
feedback loops, toensure regular opportunities for 
fertilization19,20. Glutamate and norepinephrine 
generate major excitatory signals, while γ-amino 
butyric acid (GABA) and endogenous opioids generate 
inhibitory signals19. Recently discovered factors, such 
as the RF-amide peptide superfamily [kisspeptins, 
26/43RFa, gonadotropin-inhibiting hormone (GnIH), 
RF-releasing peptides (RFRP)] also play a role19.
 Reproductive ageing is considered as a 
dysregulation of the GnRH pulse generator by a 
progressive lack of neurochemical control from other 
brain centers15,20. One of the first signals of this change 
is the monotropic increase of FSH during the early 
follicular phase, which produces the acceleration 
of follicle depletion15. Then, the interruption in the 
development of dominant follicles or withdrawal 
of estrogen without corpus luteum function causes 
extended cycles and anovulatory haemorrhages19. 
FSH acts on granulosa cells through its receptor 
(FSHr) to upregulate Cyp19a1 (commonly named as 
aromatase) and hydroxysteroid (17-β) dehydrogenase 
1 to stimulate estradiol production. FSH is critical 
for protection of follicular atresia, improvement 
of granulosa cell proliferation, and stimulates the 
upregulation of luteinizing hormone receptors (LHr) 
in these cells. Furthermore, an additional growth 
hormone, insuline-like growth factor 1 (IGF1), 
increases granulosa cell responsiveness to FSH13. As a 
result of the decreasing cohort of antral follicles, first 
inhibin B secretion reduces, then estradiol, and finally 
inhibin A secretion. This results in variations in the 
feedback mechanisms. The endocrine control of luteal 
phase does not significantly change with advancing 
age. In case ovulation still happens, the secrection of 
estradiol, progesterone, and inhibin A from the corpus 
luteum appear unchanged19,21.
Genetic causes 
 Genetic causes are considered as major factor in 
determining age at menopause in general population, 
and are described in 7 per cent of POF occurrence12,22. 
The chromosomal and genetic aberrations mostly 
involve X-chromosome, yet findings of autosomal 
involvement are reported22. Even though a large 
number of related genes have been found, with some 
understanding of their pathogenesis, the precise genetic 
mechanisms are often uncertain23.
Sex chromosome abnormalities
Aneuploidies: In various reports, chromosomal 
abnormalities, namely aneuploidies and 
rearrangements have been established as the most 
common causes of POI, corroborating the importance 
of cytogenetic testing and genetic advising24. Loss 
of one X-chromosome as X monosomy [Turner 
syndrome (TS)], in which most women present with 
gonadal dysgenesis with primary amenorrhoea and 
loss of ovarian reserve before puberty. Employing 
fluorescent in situ hybridization (FISH) and several 
specific marker to the short arm of X-chromosome 
including DXS1058, DXS6810, DXS1302 and ZXDB, 
deletion of Xp11.2-p22.1 was submitted as a critical 
zone linked to TS and POI24. In adittion, X-mosaicisms 
(45,XO, 45,XO/46,XX, 46,XX/47,XXX) are currently 
the most common chromosomal defect with incidences 
ranging from 5 to 40 per cent. Women in this group 
can present menstruation during several years before 
developing a complete POI12,25. The wide variation 
in the occurrence of chromosomal disorders possibly 
represents patient referral bias.
 One candidate gene for gonadal dysgenesis in 
these patients is USP9X (ubiquitin-specific protease 
9), which escapes the X-inactivation process and is 
located on chromosome Xp11.4, a critical region for 
ovarian development11. Other candidate genes include 
ZFX (zinc finger protein, X-linked) and BMP15 (bone 
morphogenetic protein 15). As for other aneuploidies, 
POI may be related with trisomy X (47,XXX) and 
tetrasomy (48,XXXX).
Mutations: The FMR1 (Fragile X mental retardation 
1) premutation of CGG replicates with incidence of 
1:800 in males and 1:100-200 in women, is accepted 
as the most important gene associated with POI26,27; 
is located on Xq27.323 and produces an autosomal 
dominant genetic disorder called fragile X syndrome, 
distinguished by mental retardation and other symptom 
such as hyperactivity or attention and emotional 
problems12,27. Premutation alleles befall in 7 per cent 
of sporadic POI and 21 per cent in familial POI, 
considerably higher than in general population28. 
A critical region from Xq13.3 to Xq27 has been 
characterized for ovarian development and function29,30. 
Powell et al31, employing molecular techniques, found 
a second gene (POF-2) of paternal origin situated more 
proximal to the Xq locus at Xq13.3-q21.1. Region Xq 
21.3-Xq27 is considered premature ovarian failure 1 
(POF-1). Other potential POF genes located on X- 
long arm are Diaphanous homolog 2 (DIAH2) related 
with cytoskeleton and implicated in oogenesis and 
Dachshund homolog 2 (DACH2)32. The surveillance 
suggested that transcendent genes for normal ovarian 
function are situated on both arms of the X-chromosome. 
Autosomal genes whose mutations cause some of the 
syndromes associated with the development of POF 
are : FSHR, GNAS, FOXL2, GALT, AIRE, STAR, 
CYP17A1, CYP19A1, eIF2B, NOG, ATM, POLG, 
PMM1, BMPR1B and GJA412.
Metabolic disorders
 Classical galactosaemia is triggered by mutation in 
the galactose-1-phosphate uridyl- transferase (GALT) 
gene located on chromosome 9p1333 and is a complex, 
life-threatening disease occurring during the first week 
of life and comprises various clinical abnormalities 
which, in the absence of a galactose-restricted diet, 
result to liver failure in the second half of the first 
week of life and death by acute liver and kidney 
failure within a few days34. In some cases presenting 
with a milder phenotype, the diagnosis will be made 
later in childhood when mental retardation, cataract 
and hepatomegalia will be detected. In other cases, 
galactosaemia might be completely asymptomatic, 
when a sufficient residual GALT activity is still 
continued. 
 Clinically, patients present with 
hypergonadotrophic hypogonadism in a context of 
either primary amenorrhoea with pubertal retardation 
or secondary amenorrhoea which may start at any age 
and progress to POI. However, the ovarian dysfunction 
may present transiently as a gonadotropin-resistant 
syndrome described by an alternation of periods with 
hypergonadotrophic failure and ovulatory cycles35. 
The mutations that completely eliminate GALT 
activity, such as the homozygous Q188 mutation, are 
responsible for a poor prognosis, whereas mutations 
which allow a remaining GALT activity are less likely 
to induce long-term complications36. 
 Mechanisms and timing of follicle development 
disruption are still not clear. It has been hypothesized 
that the accumulation of galactose and its toxic products 
of metabolism (galactose-I-phosphate and galactitol) 
after birth (since toxic metabolites in foetus should be 
cleared rapidly by maternal enzymes) leads to direct 
ovarian impairment36. Glycosylation defects have been 
hypothesized to account for some of the neurological 
long-term complications of galactosaemia36.
Chemotherapy irradiation and environmental toxins
 Chemotherapy and radiotherapy remain the 
cornerstone of cancer treatment. The efficacy of 
chemotherapeutic agents depends upon their ability 
to destroy rapidly dividing cells. These produce DNA 
defects as well as oxidative damage in somatic and 
germ cells. Persistent unrepaired DNA double-strand 
breaks activate apoptotic death in oocytes37. The 
clinical impact of chemotherapeutic drugs on the ovary 
is variable ranging from no effect to complete ovarian 
atrophy. The degree of damage is dependent upon the 
type of the chemotherapeutic agent used, dose given, 
age of the patient and her baseline ovarian reserve. 
The prepubertal ovary is less susceptible to damage 
by chemotherapeutic agents while older women 
have a lower ovarian reserve and therefore, are more 
susceptible to POF38.
 Alkylating agent cyclophosphamide is a non-
cell cycle-specific drug that is cytotoxic even to 
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resting cells, and results in up to 40 per cent risk of 
ovarian failure at childbearing age38. Alkylating agents 
are reported to be of high risk of gonadotoxicity, 
while vinca alkaloids, anthracyclic antibiotics, and 
antimetabolites are of relatively low risk. Histological 
examination of ovaries in females after treatment with 
chemotherapeutic drugs showed blood vessel damage, 
cortical fibrosis and reduced follicle numbers22.
 Human oocyte is susceptible to damage after 
radiation, with an estimated median lethal dose (LD50) 
of >2Gy. Damage to the ovary by radiotherapy is 
due to the age of the patient and dose of the ovarian 
exposure. The effective sterilizing dose (ESD) is the 
dose of fractionated radiotherapy at wich POI occurs 
immediately after treatment in 97.5 per cent of patients. 
ESD reduces with rising age, being 20.3 Gy at birth, 
18.4 Gy at 10 yr, 16.5 at 20 yr, and 14.3 Gy at 30 yr, 
with only 6 Gy being required to cause POI in women 
over 40 yr old39.
 All women who desire to preserve fertility should 
be advised and informed about currently available 
fertility preservation options by fertility specialists. 
Recommendations should be individualized and 
should not violate the ethical principles. Gonadotropin-
relasing hormone agonist (GnRHa) is often used in 
combination with chemotherapy causing suprression 
of the gonadotropin levels to prepubertal levels and 
reduces utero-ovarian perfusion40, these actions are 
believed to protect the follicles from apoptosis.
 Chen et al41 concluded that the use of GnRHa 
should be proposed in women of reproductive age 
receiving chemotherapy and should be given before or 
during treatment. GnRHa should begin at least 10 days 
before the beginning of chemotherapy because of the 
initial flare-up effect and should continue till two weeks 
after the end of chemotherapy42. Currently, ovarian 
tissue cryopreservation, embryo cryopreservation, 
oocyte cryopreservation and in vitro maturation are 
considered and these can be reommended in selected 
patients and should be offered only by centres with the 
necessary laboratory and surgical capability43. After 
POI prevention contraception should be considered in 
sexually active women44.
 Environmental toxins resulting in oocyte 
damage might cause POI. Smoking is the most 
widely studied toxin that alters ovarian function by 
accelerating follicular atrophy and atresia through 
increased apoptosis in primordial germ cells45. 
Polycyclic aromatic hydrocarbons (PaHs), toxic 
chemicals in tobacco, induce aromatic hydorcarbon 
receptor (Ahr)-driven expression of Bax in oocytes, 
followed by apoptosis22. Endocrine disruptors, heavy 
metals, solvents, insecticides, plastics and industrial 
chemicals, were associated with adverse reproductive 
outcomes and ovarian failure in animals. However, the 
underlying mechanisms were not yet fully clarified and 
contradictory results were found in humans23.
Immunology of POI
 Autoimmune disease is characterized by 
autoreactive T-cells and the presence of organ and 
non-organ-specific autoantibodies46,47. There are 
three different situations of autoimmune ovarian 
insufficiencies: associated with adrenal autoimmunity, 
non-adrenal autoimmunity and isolated idiopathic 
POI48.
 Initial data estimated that 10 per cent of patients 
with Addison’s disease would develop POI 5-14 
years before adrenal disorder. Addison’s disease 
infrequently develops in isolation, with the majority of 
patients having other associated endocrine disorders. 
The strongest association of POI is with autoinmune 
Addison’s disease in the context of two types of 
autoimmune polyendocrine syndromes (APS)46,47. 
Type 1 [autoimmune polyendocrinopathy candidiasis 
ectodermal dystrophy (APECED)] characterized as 
hypoparathyroidism, adrenal failure, and chronic 
mucocutaneous candidiasis occurs in young children. 
POI in the form of primary amenorrhoea develops in 
60 per cent of type I patients and type II (a polygenic 
syndrome with autoinmune Addison’s disease with 
adrenal insufficiency and other autoimmune illness 
without hypoparathyroidism)46,48 occurs in a much 
broader age range (third to fourth decade) and the 
incidence of POI is variable.
 POI may also be associated with localized or 
systemic non-adrenal disorders49,50. Between 10 and 
30 per cent of women with POI have a simultaneous 
autoimmune disease, the most commonly reported 
being hypothyroidism49,50, and the most clinically 
important hypoadrenalism; as well concurrent with 
hypoparathyroidism51, hypophysitis, type 1 diabetes 
mellitus, and non-endocrine autoimmune haemolytic 
anaemia, pernicious anaemia, vitiligo, alopecia areata, 
celiac disease, inflammatory bowel diseases, primary 
biliary cirrhosis, glomerulonephritis, multiple sclerosis, 
Sjogren’s syndrome52 and myasthenia gravis48 have 
been reported.
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Antiovarian antibodies
 A plausible hypothesis for autoimmune oophoritis 
is a selective involvement of developing follicles, 
sparing primordial follicle in early phase, with increased 
ovarian size with luteinized cyst53. This autoinmune 
disease is described by serum ovarian autoantibodies 
detected mainly by indirect immunofluorescence53 
and enzyme-linked immunosorbent assay (ELISA). 
Antigens involved in autoimmune oophoritis, such 
as zona pellucida/oocyte54, granulosa cells, theca 
cells52, corpus luteum and steroidogenic enzymes: 17 
α-hydroxylase (17α-OH), cytocrome P450 side-chain 
cleavage enzyme (p450 scc) and 21-hydroxylase47,53 
have been reported as the markers of ovarian 
autoinmunity.
Infections
 Mumps oophoritis has been considered to be a 
cause of POI. True incidence of post-oophoritis ovarian 
failure is uncertain. In the majoritiy of affected women, 
return ovarian function occurs following recovery55,56. 
HIV infection or the corresponding antiretroviral 
treatment may impair ovarian functions and fertility, 
and end in POI57. There are also anecdotal reports 
of viral and microbial infection, such as varicella, 
cytomegalovirus, malaria being followed by POI56,58. 
The true frequency of ovarian failure due to viral 
illness is uncertain.
TREATMENT AND PROGNOSIS
 After corroborating the diagnosis of POI, 
karyotyping and analysis of FMR1 premutation should 
be done to exclude major genetic causes. It is widely 
accepted that the mainstay of treatment of POI is 
hormone replacement therapy (HRT), at least until 
the average age of natural menopause. These women 
have an increased risk of premature death, mainly 
from cardiovascular disease, and POI has a potentially 
devastating influence on bone, with a decreasing 
bone mineral density, osteoporosis, and increased 
risk of fracture. Other reasons of morbidity comprise 
dementia, cognitive decrease and Parkinsonism59.
 Induction of puberty is mandatory in young 
women with pre-pubertal POI, to enable the pubertal 
growth spurt as well as for development of secondary 
sexual characteristics, but uterine morphology is often 
insufficient with failure to accomplish normal volume 
and configuration, and often a low success rate on 
oocyte donation programmes60. An extensive variety 
of treatment modalities are reported in post-pubertal 
young women, but, there is no clear evidence of best 
practice61. Physiological Sexual Steroids Replacement 
(pSSR) appears to recover uterine morphology and 
parameters of uterine fuction; however, both, age at 
POI and underlying aetiology seem to play a role in the 
success of the medication.
 Pregnancies have been shown to occur in women 
with POI62. Ovulation was reported in 20 per cent of 
patients with POI who were observed succesively over 
a 4-6-month period, but forecasting the probability 
of spontaneous remission in a specific individual is 
currently not feasible. Assisted reproductive technique 
with oocyte donation and in vitro fertilization should 
be recommended. Besides medical treatment, 
professional and family support is essential as POI can 
also adversely affect emotional health, provoke stress, 
loss of self-esteem, social isolation, increased shyness 
and anxiety.
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